What Psychiatric Genomics Consortium does

The Psychiatric Genomics Consortium (PGC) is an international, non-profit research consortium founded in 2007 and administratively hosted at the University of North Carolina. It conducts large-scale genome-wide association studies (GWAS) and statistical genetics research on psychiatric and neurodevelopmental disorders, coordinating 800+ scientists across 40+ countries through 16+ disorder-specific working groups and dedicated Global Population Groups (Africa, Latin America, South Asia, East Asia, Oceania, and Europe). Through the end of 2024, the consortium has aggregated genetic data on approximately 900,000 participants and produced more than 650 peer-reviewed publications, positioning itself as the largest biological investigation in the history of psychiatry.

PGC's deliverables are open-access scientific publications, harmonized summary-statistics datasets, and structured data-sharing infrastructure rather than commercial products. It operates a formal Data Access Committee process for qualified researchers to request individual-level data and runs complementary knowledge-dissemination assets including the PGC Video Textbook (open-access training) and monthly Worldwide Lab Meetings. Research spans the major psychiatric disorders plus functional genomics and cross-population analyses aimed at correcting ancestral imbalance in genetic studies.

The consortium's revenue model is grant-funded rather than commercial: it depends on government research grants (notably the NIH) and foundation support, with no product sales, licensing fees, or subscription revenue. Data access is provided free of charge to qualified academic researchers, and PGC does not generate commercial returns; its "customers" in a functional sense are the global scientific community and, ultimately, patients who may benefit from resulting scientific insights.

Name

Psychiatric Genomics Consortium

Legal name

Psychiatric Genomics Consortium

Website

https://pgc.unc.edu

Company type

Private

Founded year

2007

Operating status

Operating

Short description

The Psychiatric Genomics Consortium is an international, non-profit research consortium founded in 2007 that conducts large-scale genome-wide association studies across psychiatric disorders, uniting 800+ scientists across 40+ countries and producing open-access publications and datasets for the global research community.

Ownership category

akta.pro rank

Product category

Genomics Research Services

NAICS

Research and Development in the Social Sciences and Humanities (541720)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Population Genomics & Preventive Precision Health Programs (HLAAANAL)

akta.pro secondary industries

Neurogenetics & Rare Neurologic Diseases (HLAKAIAO), Public Health Genomics & Sequencing (WGS/Metagenomics) Networks (HLAJAIAK), Global Health Research, Clinical Trials & Product Development Partnerships (PDPs) (HLAJAOAM)

Keywords

• Psychiatric genomics research
• Genome-wide association studies
• Polygenic risk scores
• Genetic data consortium
• Cross-population genetics

Headquarters

HQ city

Chapel Hill

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Others

Revenue model

1. Research Grant Funding: The PGC operates as an academic research consortium funded primarily through government and foundation grants including NIH funding. Data access is provided free to researchers.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

The Psychiatric Genomics Consortium (PGC) is an international research collaboration that conducts large-scale genome-wide association studies (GWAS) and meta-analyses to identify genetic variants associated with psychiatric and neurodevelopmental disorders. It provides infrastructure for collaborative psychiatric genomics research, individual-level data access through a Data Access Portal, and freely downloadable summary statistics from published studies, organized through 16+ disorder-specific working groups spanning conditions such as schizophrenia, bipolar disorder, MDD, autism, ADHD, PTSD, OCD, and others.

Product overview

The Psychiatric Genomics Consortium (PGC) is a research consortium, not a commercial product company. It is the largest biological investigation in the history of psychiatry, comprising 800+ international scientists studying the genetics of psychiatric disorders. The PGC provides research data access, publishes scientific findings (650+ papers), offers educational resources including the PGC Video Textbook (open-access training in psychiatric genetics), and hosts Worldwide Lab Meetings for knowledge sharing among member researchers. The consortium focuses on multiple psychiatric and neurodevelopmental conditions including Alzheimer's disease, ADHD, anxiety disorders, autism, bipolar disorder, eating disorders, major depressive disorder, OCD, PTSD, schizophrenia, substance use disorders, and Tourette syndrome. Summary statistics from PGC studies are freely available for download.

Differentiator

Problem solved

Functional benefit

Products and services

• Data Access Portal A service that enables qualified academic researchers to access individual-level genetic and phenotypic data from PGC studies through a formalized Data Access Committee review process, supporting psychiatric genomics research across multiple disorder areas.
• Summary Statistics Downloads Freely downloadable summary statistics from PGC publications, enabling researchers worldwide to perform secondary analyses without applying for individual-level data access.

Quantifiable outcome

• 650+ published papers as of end of 2024
• +4 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• UK Biobank: Large-scale population genomics resource with deep phenotypic and genetic data on ~500,000 participants. Directly comparable to PGC in operating model (consortium, open data, GWAS-driven) and a frequent joint-analysis partner.
• International Cancer Genome Consortium (ICGC): Predecessor model to PGC — a globally coordinated consortium running large-scale genomic studies across multiple cancer types. Shares governance structure, working-group organization, and open summary-statistics distribution.
• GenomeAsia 100K: Population genomics consortium explicitly designed to address underrepresentation of Asian ancestries in genetic research. Closely comparable to PGC's Cross-Population Analyses Working Group mission and consortium-led model.
• NIH All of Us Research Program: US federal population genomics program aiming for 1M+ participants with deliberate diversity focus. Overlaps PGC on scale, open-access ethos, and cross-ancestry recruitment, and increasingly partners on psychiatric phenotyping.
• Genomics England: UK government-backed genomics initiative combining research and clinical infrastructure. Comparable to PGC in consortium structure, large-scale sequencing, and controlled-access data sharing for researchers.
• ENCODE Consortium: NIH-funded consortium producing functional genomics annotations. Complementary to PGC's functional and cross-disorder analyses working groups; same consortium governance and open-data ethos.

Broad incumbents

• 23andMe Research Team: Direct-to-consumer genetics company with one of the largest consumer GWAS datasets, including published psychiatric disorder analyses. Comparable scale of consented participants, but driven by consumer revenue rather than grant funding.
• deCODE genetics / Amgen: Industry-leading population genomics platform owned by Amgen, with extensive psychiatric GWAS publications. Operates commercially rather than as a consortium, but competes for the same global research prestige in psychiatric genetics.

Emerging players

• Human Cell Atlas: Global initiative to map single-cell transcriptomics across tissues. Increasingly feeds functional interpretation of psychiatric GWAS loci, putting it adjacent to PGC's downstream post-GWAS analyses.
• Allen Brain Atlas: Brain-specific gene expression and connectivity resource directly relevant to PGC's psychiatric focus. Provides the spatial and cellular context that complements PGC's variant-level discoveries.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/playlist?list=PLTQnXmu3Zkmpz-_ETmUZMPXp1hQ7XkuTt
• Xx.com/pgcgenetics

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Psychiatric Genomics Consortium